



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_47537
Title of the Manuscript:	STUDY OF INTERACTION BETWEEN TIGECYCLINE AND SULBACTAM
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments	1. Please confirm and correct some sites of mistype or misspelling errors, and error about text capitalization.	Thanks for your interest in our manuscript. The manuscript is corrected as requested. 29- S significant -> significant 38- e imipenem -> imipenem 116- proces -> process 120- tigecyline -> tigecycline 123- ttigliisin -> tigecycline 135- the the carbon -> the carbon 137- the the carbon -> the carbon
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	